Browse > Article
http://dx.doi.org/10.4333/KPS.2006.36.3.161

Implementation of Biopharmaceutics Classification System Concepts in Developing Dissolution Tests  

Sah, Hong-Kee (College of Pharmacy Ewha Womans University)
Lee, Kyung-Sin (Korea food & Drug Administration)
Baek, Min-Sun (Korea food & Drug Administration)
Publication Information
Journal of Pharmaceutical Investigation / v.36, no.3, 2006 , pp. 161-167 More about this Journal
Abstract
The objective of this study was to investigate the dissolution patterns of variety of orally administered drug products available on the market. It aimed to understand their dissolution behaviors on the basis of the biopharmaceutics classification system (BCS) concept. On the tenets of BCS, several active pharmaceutical ingredients were selected: fluoxetine hydrochloride (class I), naproxen sodium (class ll), pyridostigmine bromide (class III), furosemide (class IV) and simvastatin (class IV). Typical dissolution media used in this study were pH 1.2, pH 4 & 6.8 phosphate buffers, and water. In cases, particular dissolution media specified in the KP and/or USP were used. Dissolution patterns of fluoxetine hydrochloride and pyridostigmine bromide products were characterized by their rapid release In addition, their dissolution characteristics were relatively unaffected by the type of a dissolution medium. Similar dissolution patterns were observed with pH 1.2, pH 4 & 6.8 phosphate buffers and water. By sharp contrast, poor dissolution patterns were noticed with naproxen sodium products, when pH 1.2 and pH 4 phosphate buffer were used. Improvements in its dissolution were achieved by switching the dissolution media to pH 6.8 phosphate buffer or water. Unsatisfactory dissolution data also were observed with a simvastatin product, when it was subject to dissolution tests by use of a surfactant-free pH 1.2, pH 4 & 6.8 phosphate buffers and water. All the release patterns reported in this study were best understood when BCS concepts were implemented. Our results demonstrated that a BCS-based drug classification should be considered first to choose a dissolution test/method and set up dissolution specification.
Keywords
Biopharmaceutics classification system; Dissolution test; Bioequivalence;
Citations & Related Records
연도 인용수 순위
  • Reference
1 FDA, Center for Drug Evaluation and Research, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000
2 M. Lindenberg, S. Kopp and J.B. Dressman, Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system, Eur. J Pharm. Biopharm., 58, 265-278 (2004)   DOI   ScienceOn
3 FDA Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms, August 1997
4 M. Siewert, FIP guidelines for dissolution testing of solid oral products, Pharm. Ind., 57, 362-369 (1995)
5 FDA, Center for Drug Evaluation and Research, Guidance for Industry - Immediate release solid oral dosage forms; Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995
6 H. Sah, S.A Park, M.O. Yun and S.J. Kang, Scrutiny made to SUPAC-IR dealing with postapproval changes in immediate release solid oral dosage forms, J. Kor. Pharm. Sci., 34, 57-71 (2004)
7 FDA, Center for Drug Evaluation and Research, Guidance for Industry - Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlation, September 1997
8 FDA, Center for Drug Evaluation and Research, Guidance for Industry - SUPAC-MR: Modified release solid oral dosage forms: scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, September 1997
9 H.H. Blume and B.S. Schug, The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver, Eur. J Pharm. Biopharm., 9, 117-121 (1999)
10 식품의약품안전청 고시 제 2002-61호, 의약품동등성시험관리 규정, 2002년 11월
11 일본국립의약품식품위생연구소(National Institute of Health Sciences), Guideline for bioequivalence studies of generic products, December 1997
12 일본국립의약품식품위생연구소(National Institute of Health Sciences), Guideline for bioequivalence studies for formulation changes of oral solid dosage forms, February 2000